Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Kate Falberg
AddedMar 31, 2024
UpdatedMay 31, 2026
Kate Falberg

Kate Falberg

Board Member, UroGen Pharma

CrunchbaseLinkedIn

Kate Falberg's Career

UroGen Pharma
UroGen Pharma

New York City, NY, US

Board Member· Board
Arcus Biosciences
Arcus Biosciences

Hayward, CA, US

Board Member· Board
Halozyme Therapeutics
Halozyme Therapeutics

San Diego, CA, US

Board Member· Board
The Trade Desk
The Trade Desk

Ventura, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Kate Falberg's Career

UroGen Pharma
UroGen Pharma
Public$422.1M2002004New York City, NY, US
Board Member· Board

Leadership at UroGen Pharma

Asher HolzerAsher HolzerFounder
Liz BarrettLiz BarrettCEO
Stuart HoldenStuart HoldenBoard Member
Arie BelldegrunArie BelldegrunBoard Member
Cynthia ButittaCynthia ButittaBoard Member
Shawn TomaselloShawn TomaselloBoard Member

Similar to UroGen Pharma

Uro-1Uro-1Winston-Salem, NC, USMedical DevicesUro-1Winston-Salem, NC, US

URO-1: Innovating urology and urogynecology with breakthrough office-based medical devices.

Seed · $4.1M7
UrogpoUrogpoRocky River, OH, USPharmaceuticals, Purchasing Contractsest. 2013UrogpoRocky River, OH, US · est. 2013

UroGPO: A pharmaceutical firm offering pre-negotiated purchasing contracts and revenue development.

Pre-Seed · $1.9M75
Urica TherapeuticsUrica TherapeuticsBay Harbor Islands, FL, USPharmaceuticalsest. 2021Urica TherapeuticsBay Harbor Islands, FL, US · est. 2021

Urica Therapeutics, a Fortress Biotech subsidiary, develops pharmaceuticals for gout and kidney diseases.

Seed · $2.5M5
Bright UroBright UroAliso Viejo, CA, USMedical DevicesBright UroAliso Viejo, CA, US

Bright Uro: Pioneering next-gen urology diagnostic devices using advanced tech for actionable insights.

Series A · $29M12
Arcus Biosciences
Arcus Biosciences
Public$967M5502015Hayward, CA, US
Board Member· Board

Leadership at Arcus Biosciences

Nicole LambertNicole LambertBoard Member
Terry RosenTerry RosenCEO
Juan JaenJuan JaenCo-Founder
Yasunori KanekoYasunori KanekoBoard Member
Jennifer JarrettJennifer JarrettBoard Member
Patrick MachadoPatrick MachadoBoard Member
Halozyme Therapeutics
Halozyme Therapeutics
Public$745M3931998San Diego, CA, US
Board Member· Board

Leadership at Halozyme Therapeutics

Matt PosardMatt PosardBoard Member
Helen TorleyHelen TorleyBoard Member
Gregory FrostGregory FrostCo-Founder
Barbara DuncanBarbara DuncanBoard Member
John S. PattonJohn S. PattonCo-Founder
KarwishKarwishBoard Member

Similar to Halozyme Therapeutics

ZenomicsZenomicsDurham, NC, USDrug Deliveryest. 2015ZenomicsDurham, NC, US · est. 2015

Zenomics: Innovating diabetes treatment through advanced drug delivery systems.

Seed · $2.8M8
Heron TherapeuticsHeron TherapeuticsSan Diego, CA, USPharmaceuticalsest. 1983Heron TherapeuticsSan Diego, CA, US · est. 1983

Heron Therapeutics: A US-based biotech firm enhancing injectable pharmaceuticals via proprietary drug delivery tech.

Public · $974M203
Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
Gyre TherapeuticsGyre TherapeuticsSan Diego, CA, USBiopharmaceuticalsest. 1997Gyre TherapeuticsSan Diego, CA, US · est. 1997

San Diego-based Gyre Therapeutics develops and commercializes Hydronidone, a leading biopharmaceutical.

Public75
The Trade Desk
The Trade Desk
Public$257.5M2.8k2009Ventura, CA, US
Board Member· Board

Leadership at The Trade Desk

Peter HershbergPeter HershbergBoard Member
Eric PaleyEric PaleyBoard Member
Gokul RajaramGokul RajaramBoard Member
Jeff GreenJeff GreenBoard Member
David WellsDavid WellsBoard Member
Lise BuyerLise BuyerBoard Member

Similar to The Trade Desk

Integral Ad Science Holding CorIntegral Ad Science Holding CorNew York City, NY, USAdvertising, Verificationest. 2018Integral Ad Science Holding CorNew York City, NY, US · est. 2018

New York software company verifying digital ads globally.

Public835
OpenXOpenXPasadena, CA, USAd Exchange, Ad Serverest. 2008OpenXPasadena, CA, US · est. 2008

OpenX: A leading adtech firm offering a vast, quality ad exchange network with real-time bidding.

Series D · $70.5M200
ResponsiveAdsResponsiveAdsNew York City, NY, USAdtech, Creative Managementest. 2012ResponsiveAdsNew York City, NY, US · est. 2012

Leading adtech platform for producing, optimizing, and serving adaptable, high-impact creatives.

Pre-Seed · $390k36
DgitDgitNew York City, NY, USAdvertising, Softwareest. 1999DgitNew York City, NY, US · est. 1999

DG: A global leader in intelligent advertising solutions, managing multiscreen campaigns across broadcast and digital channels.

Public · $38M750

Kate Falberg's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Kate Falberg

Dominic CarusoDominic CarusoBoard Member · Cystic Fibrosis FoundationChris KiritsyChris KiritsyBoard Member · HTG Molecular DiagnosticsRaj IdicullaRaj IdicullaFounder · Newport HoldingsTymoteusz WojtylaTymoteusz WojtylaCo-Founder · Stream SageRobert HuginRobert HuginBoard Member · Celgene